Company · Healthcare
Sydney, NSW
Every investor coverage indicates participated in a round Garvan raised.
Investors whose own portfolio pages list Garvan, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Leftfield Group | its portfolio page ↗ |
Companies Garvan acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Garvan. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Amplia has locked in the design of its PRROSE phase two study pairing narmafotinib with chemotherapy in ovarian cancer, to run with ANZGOG across Australia and New Zealand, recruiting about 26 patients.
Biotech Amplia Therapeutics has completed planning for its PRROSE phase two trial pairing narmafotinib with chemotherapy in ovarian cancer, working with ANZGOG, with patient recruitment targeted before the end of 2026.
Veterinary biotech Gamgee has raised a four million dollar seed round led by Founders Fund, launching from Y Combinator to develop personalised mRNA cancer vaccines for dogs.
Also newshub.medianet.com.au·Dealroom·thesaasnews.com·kucoin.com